SAN FRANCISCO, Nov. 7, 2018 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing innovative gene therapy
products for patients living with serious, life-threatening rare
diseases, today announced that it will participate in the following
investor conferences in November:
- Credit Suisse 27th Annual Healthcare Conference
Natalie Holles, President and Chief
Operating Officer
Format: 1x1 Investor Meetings
Wednesday, November 14, 2018
Scottsdale, Arizona
- Evercore ISI HealthConX Conference
Matthew R. Patterson, Chairman and Chief
Executive Officer
Format: Fireside Chat
Tuesday, November 27, 2018,
10:35am EST
Boston, Massachusetts
- Piper Jaffray 30th Annual
Healthcare Conference
Matthew R.
Patterson, Chairman and Chief Executive Officer
Format: Fireside Chat
Wednesday, November 28, 2018,
11:30am EST
New York, New York
- Barclays Gene Editing & Gene Therapy
Summit
Matthew R. Patterson,
Chairman and Chief Executive Officer
Format: Corporate Presentation
Thursday, November 29, 2018,
10:15am EST
New York, New York
To access live webcasts of the fireside chats and presentation
please visit the Events & Presentations page within the
Investors + Media section of the Audentes website. Following
each conference, a replay of the live webcast will be available on
the Audentes website for approximately 30 days.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused
on developing and commercializing innovative gene therapy products
for patients living with serious, life-threatening rare
diseases. We are currently conducting
Phase 1/2 clinical studies of our lead product
candidates, AT132 for the treatment of X-linked myotubular myopathy
(XLMTM), and AT342 for the treatment of Crigler-Najjar
syndrome. We have two additional product candidates in
development, including AT982 for the treatment of Pompe disease,
and AT307 for the treatment of the CASQ2 subtype of
catecholaminergic polymorphic ventricular tachycardia
(CASQ2-CPVT). We are a focused, experienced and passionate
team committed to forging strong, global relationships with the
patient, research and medical communities.
For more information regarding Audentes, please
visit www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contact:
Katie Hogan
415.951.3398
khogan@audentestx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-participate-in-upcoming-investor-conferences-300745227.html
SOURCE Audentes Therapeutics, Inc.